Bucelipase alfa
- Generic Name
- Bucelipase alfa
- Drug Type
- Biotech
- CAS Number
- 9026-00-0
- Unique Ingredient Identifier
- 3C617U1K19
- Background
Bucelipase alfa is under investigation in clinical trial NCT00743483 (Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency).
Lipum's SOL-116 Shows Promising Phase I Results for Rheumatoid Arthritis Treatment
• Lipum has completed its Phase I clinical trial for SOL-116, demonstrating a favorable safety profile and predictable pharmacokinetics in both healthy volunteers and rheumatoid arthritis patients.
• The drug candidate targets BSSL, a protein involved in inflammation, showing direct on-target activity with reduced BSSL levels in treated participants and minimal anti-drug antibody formation.
• With backing from major shareholder Flerie AB, Lipum is now preparing to advance SOL-116 into Phase II clinical development, with GMP manufacturing already underway.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath